Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

Please enter the email address associated with your User account. Your username will be emailed to the email address on file.

THERANEXUS presents an update on the progress of its main programs and announces its cash position as of 31 December 2020

18/01/2021
Download PDF File (538Ko)

THERANEXUS, Lyon Neuroscience Research Center and CERMEP announce the creation and funding of new joint public/private laboratory “Neuroimaging for Drug Discovery” (NI2D)

18/12/2020
Download PDF File (428Ko)

The Food And Drug Administration (FDA) issues a favorable opinion on the preclinical development plan submitted by THERANEXUS and BBDF

19/11/2020
Download PDF File (318Ko)

Presentation of the results of the phase 1b clinical study of THN201 for Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease conference (CTAD)

04/11/2020
Download PDF File (605Ko)

THERANEXUS and BBDF obtain European "orphan medicinal product" designation for BBDF-101 in Batten disease

21/10/2020
Download PDF File (290Ko)